Tvardi Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
29 Nov 2022
Phase 1Phase 2
HOUSTON--(BUSINESS WIRE)-- Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitorsSTAT3 inhibitors, announced that the management team will present at the 34th Annual Piper Sandler Healthcare Conference at 1:50 p.m. ET on Thursday, December 1, 2022, in New York City as well as host one-on-one meetings throughout the day.
About Tvardi Therapeutics
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company’s lead product, TTI-101, is completing a first-in-man Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. To date, TTI-101 monotherapy has been well-tolerated and has clinical activity across a broad range of tumors including multiple durable radiographic objective responses. The company has now initiated Phase 2 clinical programs in hepatocellular carcinoma, metastatic breast cancer, and idiopathic pulmonary fibrosis. To learn more, please visit .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.